A CRO that puts its own capital where its confidence is
Shared-risk, milestone-based partnerships — and, for the right programs, private co-investment in clinical development.
Why a shared-risk model matters
Clinical trials take years and cost billions, yet only about 14% of drugs entering clinical trials win FDA approval — and the cost of a failed Phase III includes every trial that came before it.
CEBIS offers shared-risk, milestone-based costing that ties our fees to your progress. For selected programs, CEBIS will act as a private investor in clinical development — controlling the risk as the CRO running the study. Investment decisions are driven by a clinical-effect model, probability-of-success analysis and cash-flow forecasting.
Our Risk-Sharing Program targets every trial-related cause of failure
Each secondary (trial-related) factor of failure is met with a defined CEBIS solution.
| FACTOR OF FAILURE | THE CEBIS SOLUTION |
|---|---|
| Poor study design | Complete literature review; justified endpoints & sample size; early statistical planning; fewer amendments and protocol inconsistencies. |
| Ineffective site selection | Trade-off measurement per site; selection of sites with a proven track record of good recruitment. |
| Eligibility criteria | Early KOL & specialist involvement in eligibility; eligibility scenarios and risk-management planning. |
| Low recruitment rates | Improved use of recruitment funds; appropriate eligible patients; enrolling patients likely to complete the trial. |
| Low retention & adherence | Minimized travel, wait times and out-of-pocket cost; visit & treatment reminders; dedicated nurses as a permanent contact point. |
| Poor trial execution | Validated EDC/eCRF tools; automated event reporting; submission-ready data; project management for risk minimization. |
| Poor risk management | Early operational and financial risk planning; early identification and mitigation; budget-aware trade-off analysis. |
Let’s structure a partnership around your outcome
Tell us about your program and timeline. We’ll assess whether a shared-risk or co-investment model fits — and how it would work.